Monday, July 6, 2015

Stuart Millheiser & Discussion About HSPPC-96

By Jason McDonald


I believe that the discussion, when it comes to glioblastoma, can prove to be especially broad. All you have to do is look at the fact that Senator Edward Kennedy had this condition until he passed away in 2009. It is not only one of the most aggressive conditions seen in the brain but it is also the most common. With the inclusion of the vaccine referred to as HSPPC-96, though, it seems like there is even more room that can be had for discussion, whether by Stuart Millheiser or whomever.

News-Medical posted an article that spoke about an experimental vaccine that could be used in order to help those who have this condition. It would entail a degree of tumor tissue, which is needed in order to make it impactful. As the article would go on to state, patients saw increased levels of survival in comparison to what they might have had with only standard methods of care. There is quite a bit to talk about when it comes to the phase 2 trial tied to this vaccine.

When it comes to the most serious conditions in the human body, whether it's ALS or what have you, glioblastoma stands amongst them. The article went into detail about these tumors and how they seem to accelerate rather quickly, which does little to help the treatment methods that exist. Amongst them, common invasive surgery alongside chemo and radiation is viewed as the most typical procedure to help those with this condition. These stories are rightfully covered by various names, Stuart Millheiser being just one of the names to consider.

The phase 2 trial was done and it was conducted with a group of 41 adult patients, each of them possessing tumors between the years of 2007 and 2011. Each patient was given around six doses of HSPPC-96, the vaccine with the tumor tissue, as mentioned earlier. Following this implementation, the report said that 90 percent of people in the group were still alive after six months and 30 percent of them were still living after a year. To say that there is potential here would be an understatement, as I'm sure Stu Millheiser can attest to.

With a level of treatment that could potentially put tumor tissue to use, it's clear that there is still so much to learn about glioblastoma research than many of us would believe. Stem cells have been put to use as well, so it's clear that there are properties which have been hidden from us. Various studies have been done and I'd like to think that the results are indicative of what can be found later on down the road. Seeing as how survival rates have become better, it's hard to argue with such a point.




About the Author:



No comments:

Post a Comment